<DOC>
	<DOCNO>NCT02719951</DOCNO>
	<brief_summary>Glutamatergic transmission exploration use PET ( Positron Emission Tomography ) image autism compare Fragile-X Syndrome ( FXS ) Healthy Volunteers</brief_summary>
	<brief_title>Glutaminergic Transmission Autism : Molecular Imaging Exploration</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male Between 18 yearsold 45 yearsold Informed , write consent obtain patient representant Subject affiliation French social security For autistic patient : patient diagnosis ASD ( Autistic Spectrum Disorders ) follow DSMIV DSM5 criterion recommend tool ( ADIR and/or ADOS ) For FXS patient : diagnosis FXS confirmation total mutation FMR1 Contraindications MRI Excessive use alcohol drug , addiction alcohol drug last 6 month Any unstable uncontrolled disease , clinically significant Participation experimental protocol drug irradiant exam Person exclusion period previous participation experimental protocol Person temporary guardianship Forbidden treatment : psychotropic treatment 4 last week PET exam change durably glutaminergic transmission directly undirectly For healthy subject : adult guardianship , medical history central nervous system disease , medical history attention deficit hyperactivity disorder , past present psychiatric neurologic disorder ( MINI DSMIV )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>autism</keyword>
	<keyword>fragile X syndrome ( FXS )</keyword>
	<keyword>PET ( Positron Emission Tomography )</keyword>
	<keyword>glutamate</keyword>
</DOC>